Altesa BioSciences Launches Phase 2b CARDINAL Trial for Rhinovirus-Targeted COPD Treatment

Altesa BioSciences has announced the enrollment of the first patient in its phase 2b CARDINAL clinical trial, marking a significant step forward in the development of antiviral therapies for chronic obstructive pulmonary disease (COPD).

The multinational study will evaluate vapendavir, an investigational oral antiviral designed to directly target rhinovirus infections, a leading trigger of COPD exacerbations.

The trial aims to determine whether treating rhinovirus infections early can reduce respiratory symptoms, shorten illness duration, and preserve lung function in vulnerable COPD patients.

Why Rhinovirus Matters in COPD?

COPD exacerbations remain one of the leading causes of hospitalization and disease progression among respiratory patients.

According to Altesa, rhinovirus is responsible for approximately half of all acute COPD exacerbations. Despite this, current treatment approaches largely focus on symptom management after inflammation has already begun.

Katharine Knobil described the CARDINAL study as an attempt to answer a major unanswered question in respiratory medicine:

“Can directly targeting rhinovirus change the trajectory of the disease, including exacerbations?”

She noted that current care strategies often react to symptoms rather than addressing the viral trigger itself.

What Is the CARDINAL Trial?

The CARDINAL study is a phase 2b randomized, placebo-controlled multinational trial involving 900 COPD patients across the United States and the United Kingdom.

The study has been designed to mirror real-world clinical care models by proactively monitoring patients considered at high risk for respiratory infections.

How the Study Works?

Participants enrolled in the trial will:

• Be monitored over time for development of rhinovirus infections
• Undergo randomization upon confirmed infection
• Receive one of two doses of vapendavir or placebo

The study’s primary endpoint focuses on improvement in respiratory symptoms using validated patient-reported outcome measures. Researchers will also evaluate:

• Time to symptom resolution
• Quality of life outcomes
• Healthcare resource utilization
• Lung function preservation
• Dose selection for future phase 3 studies

What Is Vapendavir?

Vapendavir is an investigational broad-spectrum antiviral drug administered orally in pill form. The therapy is designed to:

• Prevent rhinoviruses from entering human cells
• Block viral replication inside the body

According to the company, vapendavir has demonstrated activity against:

• All three rhinovirus species
• RV-C strains
• Other respiratory enteroviruses

Unlike conventional COPD therapies that primarily address inflammation or airway constriction, vapendavir aims to interrupt the viral trigger responsible for exacerbations before the inflammatory cascade escalates.

Building on Earlier Clinical Data

The CARDINAL trial follows Altesa’s previously completed phase 2a Challenge Study in COPD patients. That earlier study reportedly demonstrated that vapendavir:

• Improved upper airway symptoms
• Improved lower airway symptoms
• Reduced illness duration
• Better maintained small airway lung function compared to placebo

The phase 2b trial is expected to provide larger-scale data to validate these findings in real-world patient populations.

A Potential Shift in COPD Treatment Strategy

If successful, vapendavir could represent a major shift in COPD management. Current COPD treatment strategies primarily rely on:

• Bronchodilators
• Corticosteroids
• Antibiotics
• Symptom control during exacerbations

A targeted antiviral approach introduces the possibility of preventing or reducing exacerbations at their viral source. This strategy could be especially important because repeated exacerbations accelerate:

• Lung function decline
• Hospitalization risk
• Mortality
• Healthcare costs

Beyond COPD: Broader Respiratory Applications

While the immediate focus remains COPD, Altesa believes vapendavir may have broader applications in other respiratory conditions triggered or worsened by viral infections.

Potential future indications include:

• Asthma
• Chronic lung diseases
• Other high-risk respiratory populations

Given the widespread role respiratory viruses play in chronic airway inflammation, antivirals like vapendavir could eventually become part of a broader respiratory disease management strategy.

Final Thoughts

The launch of the CARDINAL trial reflects growing interest in precision antiviral therapies for chronic respiratory diseases.

Rather than treating only the downstream inflammation caused by viral infections, Altesa is pursuing a strategy aimed at the root trigger itself.

If vapendavir can successfully reduce rhinovirus-driven COPD exacerbations in larger clinical trials, it may open the door to an entirely new treatment category in respiratory medicine.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!